Date: 2012-05-03
Type of information: Company acquisition
Acquired company: AmniSure International (USA - MA)
Acquiring company: Qiagen (The Netherlands)
Amount: undisclosed
Terms: * On May 3, 2012, Qiagen announced the acquisition of AmniSure International LLC, a privately owned Boston company that markets the AmniSure assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely. Financial terms of the agreement to acquire AmniSure, a privately held company, were not disclosed. Qiagen expects this acquisition to be neutral to adjusted diluted earnings per share (EPS) in 2012, but to be accretive by approximately $0.02 in 2013. The acquisition of AmniSure is expected to contribute approximately $12 million to Qiagen for the remainder of 2012 and full-year sales of approximately $24 million in 2013. Furthermore, Qiagen expects to incur one-time charges and integration costs of approximately $5 million in 2012 which primarily relate to restructuring efforts and integration activities in connection with the transaction. The closing was completed in May 2012, upon which AmniSure became a wholly owned subsidiary ofQiagen and its results began to be consolidated. AmniSure was advised in this transaction by William Blair & Company.
Details: AmniSure International is a privately owned Boston company that markets the AmniSure assay for determining whether a pregnant woman is suffering rupture of fetal membranes (ROM), a condition in which fluid leaks from the amniotic sac prematurely. AmniSure has been cleared by the FDA for marketing and is reimbursable under most U.S. state Medicaid plans. The product is also approved in other markets around the world. The AmniSure test is a one-step, minimally invasive test strip using proprietary technology to detect tiny quantities of amniotic fluid in vaginal discharge. Results are available in minutes at the point of care. Accuracy of the AmniSure test is documented in multiple clinical studies and approaches 99% - far superior to traditional methods.QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
Related: diagnostic
